New drugs of abuse

Pharmacotherapy

Volumn 35, Issue 2, 2015, Pages 189-197

  Rech, Megan A ^a   Donahey, Elisabeth ^a   Cappiello Dziedzic, Jacqueline M ^a,b   Oh, Laura ^a,b   Greenhalgh, Elizabeth ^a,c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

desomorphine; kratom; salvia; synthetic cannabinoids; synthetic cathinones

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; BENZODIAZEPINE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CATHINONE; DESOMORPHINE; DEXMEDETOMIDINE; HERBACEOUS AGENT; KRATOM; MITRAGYNINE; MORPHINE DERIVATIVE; NEUROLEPTIC AGENT; PROPOFOL; RECREATIONAL DRUG; SALVINORIN A; SODIUM CHLORIDE; UNCLASSIFIED DRUG; DESIGNER DRUG; STREET DRUG;

ARTICLE; BINDING AFFINITY; DRUG ABSORPTION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFECT; DRUG EXPOSURE; DRUG OVERDOSE; DRUG RECEPTOR BINDING; ENZYME DEGRADATION; FIRST PASS EFFECT; GROUPS BY AGE; HUMAN; MEDICAL HISTORY; NONHUMAN; PHYSICAL EXAMINATION; SALVIA; WITHDRAWAL SYNDROME; ANIMAL; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

ANIMALS; DESIGNER DRUGS; DRUG OVERDOSE; HUMANS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84923492552     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1522     Document Type: Article

References (67)

1. Rosenbaum CD, Carreiro SP, Babu KM,. Here today, gone tomorrow⋯ and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012; 8: 15-32.
2. Text of S. 3190 (112th): Synthetic Drug Abuse Prevention Act of 2012 (Introduced version). GovTrack.us. Available from https://www.govtrack.us/congress/bills/112/s3190/text. Accessed March 4, 2014.
3. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, & Center for Behavioral Health Statistics and Quality. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Illicit Drugs. Available from http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm#ch2. Accessed March 4, 2014.
4. Erickson TB, Thompson TM, Lu JJ,. The approach to the patient with an unknown overdose [abstract vii]. Emerg Med Clin North Am 2007; 25: 249-81.
5. Frithsen IL, Simpson WM Jr,. Recognition and management of acute medication poisoning. Am Fam Physician 2010; 81: 316-23.
6. Meyer MR, Du P, Schuster F, Maurer HH,. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 2010; 45: 1426-42.
7. Nelson ME, Bryant SM, Aks SE,. Emerging drugs of abuse. Emerg Med Clin North Am 2014; 32: 1-28.
8. Sutter ME, Chenoweth J, Albertson TE,. Alternative drugs of abuse. Clin Rev Allergy Immunol 2014; 46: 3-18.
9. Alles GA, Fairchild MD, Jensen M, Alles A,. Chemical pharmacology of Catha edulis. J Med Chem 1960; 3: 323-52.
10. Mas-Morey P, Visser MHM, Winkelmolen L, Touw DJ,. Clinical toxicology and management of intoxications with synthetic cathinones ("bath salts"). J Pharm Pract 2013; 26: 353-7.
11. Benzer TI, Nejad SH, Flood JG,. Case records of the Massachusetts General Hospital. Case 40-2013. A 36-year-old man with agitation and paranoia. N Engl J Med 2013; 369: 2536-45.
12. Prosser JM, Nelson LS,. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2011; 8: 33-42.
13. Valente MJ, Guedes de Pinho P, Lourdes Bastos M, Carvalho F, Carvalho M,. Khat and synthetic cathinones: a review. Arch Toxicol 2013; 88: 15-45.
14. Bath Salts. Available from http://www.aapcc.org/alerts/bath-salts/. Accessed April 12, 2014.
15. Kasick DP, McKnight CA, Klisovic E,. "Bath salt" ingestion leading to severe intoxication delirium: two cases and a brief review of the emergence of mephedrone use. Am J Drug Alcohol Abuse 2012; 38: 176-80.
16. Marinetti LJ, Antonides HM,. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol 2013; 37: 135-46.
17. Warrick BJ, Hill M, Hekman K., A 9-state analysis of designer stimulant, "bath salt," hospital visits reported to poison control centers. Ann Emerg Med 2013; 62: 244-51.
18. Adebamiro A, Perazella MA,. Recurrent acute kidney injury following bath salts intoxication. Am J Kidney Dis 2012; 59: 273-5.
19. Rojek S, Kłys M, Strona M, Maciõw M, Kula K,. "Legal highs"-toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-MBDB administration. Forensic Sci Int 2012; 222: e1-6.
20. Carbone PN, Carbone DL, Carstairs SD, Luzi SA,. Sudden cardiac death associated with methylone use. Am J Forensic Med Pathol 2013; 34: 26-8.
21. Emerson TS, Cisek JE,. Methcathinone: a Russian designer amphetamine infiltrates the rural Midwest. Ann Emerg Med 1993; 22: 1897-903.
22. Banks ML, Worst TJ, Rusyniak DE, Sprague JE,. Synthetic cathinones ("bath salts"). J Emerg Med 2014; 46 (5): 632-42. doi: 10.1016/j.jemermed.2013.11.104.
23. European Monitoring Centre for Drugs and Drug Addiction: EMCDDA 2009 Thematic paper-understanding the "Spice" phenomenon.
24. Vardakou I, Pistos C, Spiliopoulou C,. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010; 197: 157-62.
25. Gunderson EW,. Synthetic cannabinoids: a new frontier of designer drugs. Ann Intern Med 2013; 159: 563-4.
26. Johnston LD, O'Malley PM, Miech RA, Bachman JG, Schulenberg JE,. Monitoring the Future National Survey Results on Drug Use 1975-2013. 2013 Overview. Key findings on adolescent drug use. Available from http://monitoringthefuture.org//pubs/monographs/mtf-overview2013.pdf. Accessed February 21, 2014.
27. McCarberg BH, Barkin RL,. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther 2007; 14: 475-83.
28. Harris CR, Brown A,. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013; 44: 360-6.
29. Teske J, Weller JP, Fieguth A, Rothämel T, Schulz Y, Tröger HD,. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2010; 878: 2659-63.
30. Hall W, Degenhardt L,. Adverse health effects of non-medical cannabis use. Lancet 2009; 374: 1383-91.
31. Seely KA, Lapoint J, Moran JH, Fattore L,. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 234-43.
32. Brents LK, Gallus-Zawada A, Radominska-Pandya A, et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 2012; 83: 952-61.
33. Schneir AB, Cullen J, Ly BT,. "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med 2011; 40: 296-9.
34. The White House. Synthetic Drugs (a.k.a. K2, Spice, Bath Salts, etc.). Available from http://www.whitehouse.gov/ondcp/ondcp-fact-sheets/synthetic-drugs-k2-spice-bath-salts. Accessed March 19, 2014.
35. Papanti D, Schifano F, Botteon G, et al. "Spiceophrenia": a systematic overview of "spice"-related psychopathological issues and a case report. Hum Psychopharmacol 2013; 28: 379-89.
36. Stefanis NC, Delespaul P, Henquet C, Bakoula C, van Os J,. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004; 99: 1333-41.
37. Zimmermann US, Winkelmann PR, Pilhatsch M, et al. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold." Dtsch Arztebl Int 2009; 106: 464-7.
38. Forrester M, Kleinschmidt K, Schwarz E, Young A,. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol 2012; 31: 1006-11.
39. Castellanos D, Singh S, Thornton G, Avila M, Moreno A,. Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 2011; 49: 347-9.
40. Vohra R, Seefeld A, Cantrell FL, Clark RF,. Salvia divinorum: exposures reported to a statewide poison control system over 10 years. J Emerg Med 2011; 40: 643-50.
41. Braida D, Limonta V, Capurro V, et al. Involvement of κ-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry 2008; 63: 286-92.
42. Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H,. In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica 2009; 39: 391-8.
43. Kelly BC,. Legally tripping: a qualitative profile of Salvia divinorum use among young adults. J Psychoactive Drugs 2011; 43: 46-54.
44. Mowry M, Mosher M, Briner W,. Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychoactive Drugs 2003; 35: 379-82.
45. Przekop P, Lee T,. Persistent psychosis associated with salvia divinorum use. Am J Psychiatry 2009; 166: 832.
46. Paulzen M, Gründer G,. Toxic psychosis after intake of the hallucinogen salvinorin A. J Clin Psychiatry 2008; 69: 1501-2.
47. Forrester MB,. Kratom exposures reported to Texas poison centers. J Addict Dis 2013; 32: 396-400.
48. Vicknasingam B, Narayanan S, Beng GT, Mansor SM,. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy 2010; 21: 283-8.
49. Stolt A-C, Schroder H, Neurath H, et al. Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract. Psychopharmacology 2014; 231: 13-25.
50. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH,. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction 2008; 103: 1048-50.
51. Prozialeck WC, Jivan JK, Andurkar SV,. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc 2012; 112: 792-9.
52. KRATOM (Mitragyna speciosa korth) (Street Names: Thang, Kakuam, Thom, Ketum, Biak). Available from http://www.deadiversion.usdoj.gov/drug-chem-info/kratom.pdf. Accessed February 4, 2014.
53. Nelsen JL, Lapoint J, Hodgman MJ, Aldous K,. Seizure and coma following kratom (Mitragynina speciosa Korth) exposure. J Med Toxicol 2010; 6: 424-6.
54. Roche K, Hart K, Sangalli B,. Kratom: a case of a legal high. Clin Toxicol 2008; 46: 598.
55. Kapp FG, Maurer HH, Auwärter V, Winkelmann M, Hermanns-Clausen M,. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol 2011; 7: 227-31.
56. Sheleg SV, Collins GB,. A coincidence of addiction to "Kratom" and severe primary hypothyroidism. J Addict Med 2011; 5: 300-1.
57. Arndt T, Claussen U, Gussregen B, et al. Kratom alkaloids and O-desmethyltramadol in urine of a "Krypton" herbal mixture consumer. Forensic Sci Int 2011; 208: 47-52.
58. Kronstrand R, Roman M, Thelander G, Eriksson A,. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol 2011; 35: 242-7.
59. Holler JM, Vorce SP, McDonough-Bender PC, Magluilo J Jr, Solomon CJ, Levine B,. A drug toxicity death involving propylhexedrine and mitragynine. J Anal Toxicol 2011; 35: 54-9.
60. Matsumoto K, Horie S, Takayama H, et al. Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life Sci 2005; 78: 2-7.
61. McWhirter L, Morris S,. A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence. Eur Addict Res 2010; 16: 229-31.
62. Takayama H,. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo) 2004; 52: 916-28.
63. Grund J-PC, Latypov A, Harris M,. Breaking worse: the emergence of krokodil and excessive injuries among people who inject drugs in Eurasia. Int J Drug Policy 2013; 24: 265-74.
64. DESOMORPHINE (Dihydrodesoxymorphine; dihydrodesoxymorphine-D; Street Name: Krokodil, Crocodil). Available from http://www.deadiversion.usdoj.gov/drug-chem-info/desomorphine.pdf. Accessed February 27, 2014.
65. Thekkemuriyi DV, John SG, Pillai U,. "Krokodil"-a designer drug from across the Atlantic, with serious consequences. Am J Med 2014; 127: e1-2.
66. Eddy NB, Halbach H, Braenden OJ,. Synthetic substances with morphine-like effect: clinical experience; potency, side-effects, addiction liability. Bull World Health Organ 1957; 17: 569-863.
67. Gahr M, Freudenmann RW, Hiemke C, et al. Desomorphine goes "crocodile." J Addict Dis 2012; 31: 407-12.